| Date Filed | Type | Description |
| 10/28/2022 |
SC 13D/A
| New Enterprise Associates 16, L.P. reports a 11.6% stake in Akouos, Inc. |
| 10/11/2022 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 7.3% stake in Allakos Inc. |
| 05/27/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/25/2022 |
SC 13D/A
| New Enterprise Associates 16, L.P. reports a 42.5% stake in Trevi Therapeutics, Inc. |
| 01/05/2022 |
SC 13D/A
| New Enterprise Associates 16, L.P. has filed a Schedule 13D for Metacrine, Inc. |
| 11/02/2021 |
SC 13D/A
| New Enterprise Associates 16, L.P. reports a 36.1% stake in Trevi Therapeutics, Inc. |
| 04/13/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/26/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/10/2021 |
SC 13D/A
| New Enterprise Associates 16, L.P. has filed a Schedule 13D for Allakos Inc. |
| 09/28/2020 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 11.8% stake in Metacrine, Inc. |
| 08/03/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/07/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 04/16/2020 |
SC 13D/A
| New Enterprise Associates 16, L.P. reports a 33.3% stake in Trevi Therapeutics, Inc. |
| 02/13/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 07/30/2019 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 18.2% stake in Mirum Pharmaceuticals, Inc. |
| 06/28/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/28/2019 |
SC 13D/A
| New Enterprise Associates 16, L.P. has filed a Schedule 13D for X4 Pharmaceuticals, Inc. |
| 05/20/2019 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 25% stake in Trevi Therapeutics, Inc. |
| 02/22/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/25/2018 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 17.8% stake in Marker Therapeutics, Inc. |
| 07/27/2018 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 5.6% stake in Allakos Inc. |
| 01/26/2018 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 11/29/2017 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |